Skip to main content
SpringerLink
Log in

Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Well-nourished patients with dilated cardiomyopathy (DCM) show slight reduction of mean basal IGF-I levels which, however, display a response to a rhGH dose as low as 5.0 μg/kg/day similar to that of age-matched control subjects (CS). To further investigate peripheral GH sensitivity, we studied the IGF-I and IGFBP-3 responses to 4-day sc 2.5 μg/kg/day rhGH administration, the lowest effective dose able to increase IGF-I levels in normal subjects, in 10 DCM patients [age (mean±SE): 57.6±1.0 yr, body mass index (BMI): 24.0±1.2 kg/m2, left ventricular ejection fraction: 26.2±3.2%, NYHA (New York Heart Association): I/0, II/4, III/4, IV/2] and in 9 age-matched healthy CS (age: 55.3±1.2 yr, BMI: 23.7±1.8 kg/m2). Basal IGF-I levels in DCM were lower though not significantly than those in CS (147.7±9.8 vs 174.7±17.0 μg/l). Basal IGFBP-3 levels in DCM were similar to those in CS (3.1±0.3 vs 2.7±0.2 mg/l). In CS 4-day rhGH increased IGF-I levels (222.4±14.9 μg/l; p<0.01 vs baseline) but did not modify IGFBP-3 levels (3.0±0.2 mg/l). In DCM IGF-I levels were increased by 4-day rhGH administration (175.7±11.0 μg/l; p<0.05 vs baseline) with a similar percent extent than in CS. On the other hand, in DCM, but not in CS, 4-day rhGH significantly increased IGFBP-3 levels (3.5±0.3 mg/l; p<0.05 vs baseline). Therefore, in conclusion, testing with the lowest effective rhGH dose further suggest that peripheral GH sensitivity in well-nourished DCM is preserved. On the other hand, DCM patients show enhanced IGFBP-3 sensitivity to stimulation by rhGH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saccà L., Cittadini A., Fazio S. Growth Hormone and the heart. Endocr. Rev. 1994, 15: 555–573.

    Article  PubMed  Google Scholar 

  2. De Boer H., Blok G.J., Van der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocr. Rev. 1995, 16: 63–86.

    Article  PubMed  Google Scholar 

  3. Fazio S., Sabatini D., Capaldo B., Vigorito C., Giordano A., Guida R., Pardo F., Biondi B., Saccà L. A preliminary study of Growth Hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 1996, 334: 809–814.

    Article  CAS  PubMed  Google Scholar 

  4. Osterziel K.J., Strohm O., Schuler J., Friedrich M., Hanlein D., Willenbrock R., Anker S.D., Poole-Wilson P.A., Ranke M.B., Dietz R. Randomized, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998, 351: 1233–1237.

    Article  CAS  PubMed  Google Scholar 

  5. Anker S.D., Chua T.P., Ponikowski P., Harrington D., Swan J.W., Kox W.J., Poole-Wilson P.A., Coats A.J.S. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997, 96: 526–534.

    Article  CAS  PubMed  Google Scholar 

  6. Niebauer J., Pflaum C.D., Clark A.L., Strasburger C.J., Hooper J., Poole-Wilson P.A., Coats A.J.S., Anker S.D. Deficient Insulin-like Growth Factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J. Am. Coll. Cardiol. 1998, 32: 393–397.

    Article  CAS  PubMed  Google Scholar 

  7. Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the Insulin-like growth factors. Endocr. Rev. 1994, 15: 80–101.

    CAS  PubMed  Google Scholar 

  8. Gianotti L., Broglio F., Aimaretti G., Arvat E., Colombo S., Di Summa M., Gallioli G., Pittoni G., Sardo E., Stella M., Zanello M., Miola C., Ghigo E. Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions. J. Endocrinol. Invest. 1998, 21: 115–121.

    CAS  PubMed  Google Scholar 

  9. Broglio F., Fubini A., Morello M., Arvat E., Aimaretti G., Gianotti L., Boghen M.F., Deghenghi R., Mangiardi L., Ghigo E. Activity of GH/IGF-I axis in patients with dilated car-diomyopathy. Clin. Endocrinol. (Oxf) 1999, 50: 417–430.

    Article  CAS  Google Scholar 

  10. Ghigo E., Aimaretti G., Maccario M., Fanciulli G., Arvat E., Minuto F., Giordano G., Delitala G., Camanni F. Dose-response study of the GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am. J. Physiol. 1999, 276: E1009–E1013.

    CAS  PubMed  Google Scholar 

  11. Sahn D.J., De Maria A., Kisslo J., Weyman A. Recommendation regarding quantitation in M-mode echocardiography: results of a survey of echocar- diographic measurements. Circulation 1978, 58: 1072–1083.

    Article  CAS  PubMed  Google Scholar 

  12. Schiller N.B., Shahn P.M., Crawford M., De Maria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnittger I. Recommendation for quantitation of the left ventricle by two-dimensional echocardiography. J. Am. Soc. Echocardiogr. 1989, 2: 358–367.

    CAS  PubMed  Google Scholar 

  13. Giustina A., Lorusso R., Borghetti V., Bugari G., Misitano V., Alfieri O. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy. Am. Heart J. 1996, 131: 620–622.

    Article  CAS  PubMed  Google Scholar 

  14. Mangieri E., Tosti-Croce C., Tanzilli G., Barillà F., Nardi M., Poggi M., Ciavolella M., Farinelli A., Mangiaracina F., Campa P.P. Impairment of Growth hormone/Insulin-like growth factor-I axis in normopituitaric patients with biven-tricular cardiac failure and hepatic stasis. Cardiologia 1996, 41: 449–453.

    CAS  PubMed  Google Scholar 

  15. Volterrani M., Desenzani P., Lorusso R., d’Aloia A., Manelli F., Giustina A. Haemodinamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997, 359: 1067–1068.

    Article  Google Scholar 

  16. Baumann G. Growth hormone heterogeneity: genes, isohormo-nes, variants and binding proteins. Endocr. Rev. 1991, 12: 424–449.

    Article  CAS  PubMed  Google Scholar 

  17. Rajaram S., Baylink D.J., Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr. Rev. 1997, 18: 801–831.

    CAS  PubMed  Google Scholar 

  18. De Boer H., Blok J., Popp-Snijders C., Stuurman L., Baxter R.C., Van der Veen E. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum marker. J. Clin. Endocrinol. Metab. 1996, 81: 1371–1376.

    PubMed  Google Scholar 

  19. Aimaretti G., Corneli G., Razzore P., Bellone S., Baffoni C., Bellone J., Camanni F., Ghigo E. Usefulness of IGF-I assay for the diagnosis of GH de ficiency in adults. J. Endocrinol. Invest. 1998, 21: 506–511.

    CAS  PubMed  Google Scholar 

  20. Hall K., Hilding A., Thoren M. Determinants of circulating insulin-like growth factor-I. J. Endocrinol. Invest. 1999, 22: 48–57.

    CAS  PubMed  Google Scholar 

  21. Juul A., Dalgaard P., Blum W.F., Bang P., Hall K., Michaelsen K.F., Muller J., Skakkebaek M. Serum levels of insulin-like growth factor (IGF)-bind- ing protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J. Clin. Endocrinol. Metab. 1995, 80: 2534–2542.

    CAS  PubMed  Google Scholar 

  22. Noll K., Wegmann B.R., Havemann K., Jaques G. Insulin-like growth factors stimulate the release of insulinlike growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines. J. Clin. Endocrinol. Metab. 1996, 81: 2653–2662.

    CAS  PubMed  Google Scholar 

  23. Rosen C.J., Conover C. Growth hormone/insulin-like growth factor-I axis in aging: a summary of a National Institutes of Aging-Sponsored Symposium. J. Clin. Endocrinol. Metab. 1997, 82: 3919–3922.

    CAS  PubMed  Google Scholar 

  24. Rechler M. Editorial: Growth inhibition by Insulin-like growth factor (IGF) binding protein-3. What’s IGF got to do with it? Endocrinology 1997, 138: 2645–2647.

    CAS  PubMed  Google Scholar 

  25. Tucci M., Nygard K., Tanswell B.V., Farber H.W., Hill D.J., Han V.K.M. Modulation of insulin-like growth factor (IGF) and IGF binding protein byosynthesis by hypoxia in cultured vascular endothelial cells. J. Endocrinol. 1998, 157: 13–24.

    Article  CAS  PubMed  Google Scholar 

  26. Leyva F., Anker S., Swan J.W., Godsland I.F., Wingrove C.S., Chua T.P., Stevenson J.C., Coats A.J.S. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart J. 1997, 18: 858–865.

    Article  CAS  PubMed  Google Scholar 

  27. Jones J., Clemmons D.R. Insulin-like growth factor and their binding proteins: biological actions. Endocr. Rev. 1995, 16: 3–34.

    CAS  PubMed  Google Scholar 

  28. Chen W.H., Pellegata N.S., Wang P.H. Coordinated effects of insulin-like growth factor I on inhibitory pathways of cell cycle progression in cul tured cardiac muscle cells. Endocrinology 1995, 136: 5240–5243.

    CAS  PubMed  Google Scholar 

  29. Wang L., Ma W., Markovich R., Chen J.W., Wang P.H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ. Res. 1998, 83: 516–522.

    Article  CAS  PubMed  Google Scholar 

  30. Oh Y. IGBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth. Endocrine 1997, 7: 111–113.

    Article  CAS  PubMed  Google Scholar 

  31. Juul A., Main K., Blum W.F., Lindholm J., Ranke M.B., Skakkebaek N.E. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin. Endocrinol. (Oxf.) 1994, 41: 85–93.

    Article  CAS  Google Scholar 

  32. Benbassat C.A., Maki K.C., Unterman T.G. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J. Clin. Endocrinol. Metab. 1997, 82: 1484–1491.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Endocrinologia e, Università di Torino, C.so Dogliotti 14, 10126, Torino, Italy

    F. Broglio, A. Benso, E. Arvat, G. Aimaretti, C. Gottero, R. Granata, M. F. Boghen, F. Camanni & E. Ghigo M.D.

  2. Divisione di Cardiologia, Dipartimento di Medicina Interna, Università di Torino, Italy

    M. Bobbio

Authors
  1. F. Broglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Benso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Arvat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Aimaretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Gottero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Granata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. F. Boghen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Bobbio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. Camanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Ghigo M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Ghigo M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Broglio, F., Benso, A., Arvat, E. et al. Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy. J Endocrinol Invest 23, 520–525 (2000). https://doi.org/10.1007/BF03343768

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343768

Key-words

Search

Navigation